Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection
Authors
Keywords
CAR T cells, cell therapies, immunogenicity, humoral response, anti-CAR IgG, IdeS
Journal
MOLECULAR THERAPY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-07-02
DOI
10.1016/j.ymthe.2021.06.022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunogenicity of CAR T cells in cancer therapy
- (2021) Dimitrios L. Wagner et al. Nature Reviews Clinical Oncology
- Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T Cell Therapy
- (2021) Kitsada Wudhikarn et al. BLOOD
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- Recent Advances in Allogeneic CAR-T Cells
- (2020) Dong Wook Kim et al. Biomolecules
- Engineering tolerance toward allogeneic CAR-T cells by regulation of MHC surface expression with Human Herpes Virus-8 proteins
- (2020) Xiaomei Wang et al. MOLECULAR THERAPY
- Next-generation cell therapies: the emerging role of CAR-NK cells
- (2020) Rafet Basar et al. Blood Advances
- Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
- (2019) Rita Kansal et al. Science Translational Medicine
- Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
- (2019) Boris Gorovits et al. BIODRUGS
- Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
- (2019) Stefan Stoiber et al. Cells
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity
- (2019) Alejandro Torres Chavez et al. Journal for ImmunoTherapy of Cancer
- Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
- (2018) Ping-Pin Zheng et al. DRUG DISCOVERY TODAY
- An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
- (2018) Matthew L Cooper et al. LEUKEMIA
- Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population
- (2018) Vijaya L. Simhadri et al. Molecular Therapy-Methods & Clinical Development
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Antibody-Mediated Rejection of Solid-Organ Allografts
- (2018) Alexandre Loupy et al. NEW ENGLAND JOURNAL OF MEDICINE
- IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barré syndrome
- (2017) Yuzhong Wang et al. EXPERIMENTAL NEUROLOGY
- Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy
- (2017) Sofia Järnum et al. MOLECULAR CANCER THERAPEUTICS
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation
- (2017) Stanley C. Jordan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
- (2017) Oladapo O. Yeku et al. Scientific Reports
- CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
- (2017) Yongping Zhang et al. Frontiers of Medicine
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
- (2016) Kole T. Roybal et al. CELL
- Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors
- (2016) Leonardo Morsut et al. CELL
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
- (2016) C. T. Ellebrecht et al. SCIENCE
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Optimization of Pre-transplantation Conditions to Enhance the Efficacy of Mesenchymal Stem Cells
- (2015) Nazmul Haque et al. International Journal of Biological Sciences
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1
- (2015) Tao Dao et al. NATURE BIOTECHNOLOGY
- Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
- (2015) C.-Y. Wu et al. SCIENCE
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
- (2013) Alexandre Loupy et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
- (2011) M. Chmielewski et al. CANCER RESEARCH
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
- (2010) C. H. J. Lamers et al. BLOOD
- Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes
- (2010) R. Yang et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
- (2008) B. G. Till et al. BLOOD
- IdeS: A Bacterial Proteolytic Enzyme with Therapeutic Potential
- (2008) Björn P. Johansson et al. PLoS One
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now